CellCentric

CellCentric

Signal active

Organization

Contact Information

Overview

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.

The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

About

Industries

Biotechnology, Medical, Therapeutics

Founded

2003

Employees

1-10

Headquarters locations

Cambridge, Cambridgeshire, United Kingdom, Europe

Social

Profile Resume

CellCentric headquartered in Europe, operates in the Biotechnology, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $29.3B in funding across 216 round(s). With a team of 1-10 employees, CellCentric is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - CellCentric, raised $6.6M. Discover more about their projects, partnerships, and impact on our platform.

Employees

imagePlace Will West

Will West

CEO

imagePlace Karen Clegg

Karen Clegg

Clinical Operations Director

imagePlace Thea Stanway

Thea Stanway

Finance Director & Company Secretary

Funding Rounds

Funding rounds

18

Investors

4

Lead Investors

0

Total Funding Amount

$135.6M

Details

2

CellCentric has raised a total of $135.6M in funding over 2 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2011Early Stage Venture
2004Early Stage Venture

Investors

CellCentric is funded by 45 investors.

Investor NameLead InvestorFunding RoundPartners
5Y Capital-FUNDING ROUND - 5Y Capital6.6M
UK Innovation & Science Seed Fund-FUNDING ROUND - UK Innovation & Science Seed Fund6.6M
CellCentric-FUNDING ROUND - CellCentric6.6M
Future Planet Capital-FUNDING ROUND - Future Planet Capital6.6M